Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy

Arlington (VA): American Diabetes Association; 2022 Feb.
Affiliations
Free Books & Documents
Review

Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy

Rodica Pop-Busui et al.
Free Books & Documents

Excerpt

Diabetic neuropathies are the most common chronic complications of diabetes, with an estimated lifetime prevalence exceeding 50% in people with diabetes. Among various forms of neuropathy, diabetic peripheral neuropathy (DPN) is the most common and has the strongest evidence base regarding therapeutic approaches. This American Diabetes Association clinical compendium summarizes the latest information about screening for, diagnosing, and treating painful DPN in routine clinical practice. It opens with an overview of the epidemiology of DPN, followed by a description of the pathophysiology of the disease and its often severely painful symptoms. The authors recommend a stepwise approach to effectively diagnose DPN and offer a novel perspective on the impact of social determinants of health on the development and management of DPN. They summarizes the latest guidance on effective therapies, including pharmacological oral and topical agents, nutraceutical products, and nonpharmacological therapies, including physical activity and dietary interventions, passive modalities, and energy or nerve stimulation techniques. Throughout the publication, the authors identify knowledge gaps that need to be addressed and advocate a personalized care approach to reduce the burden of painful DPN and optimize quality of life for individuals affected by it.

PubMed Disclaimer

Conflict of interest statement

Duality of Interest

R.P.-B. has served on advisory boards for Averitas Pharma, Boehringer Ingelheim, Novo Nordisk, and Nevro.

D.Z. has served as a consultant to Allergan, Bayer, Berlin-Chemie, Biogen, Cannaxan, Clexio, Grünenthal, Mitsubishi Tanabe, Mundipharma, Nevro, Novaremed, Novartis, Pathways Public Health, Pfizer, Procter & Gamble, Stada, Takeda, Viatris, and Wörwag; he has been a speaker for Astellas, AstraZeneca, Berlin-Chemie, Mundipharma, Pfizer, Sanofi, Takeda, Viatris, and Wörwag; and he has received research support from Mitsubishi Tanabe, Novartis, and Wörwag.

No other potential conflicts of interest relevant to this work were reported.

Similar articles

Grants and funding

This publication has been supported by an unrestricted educational grant to the American Diabetes Association from Nevro, Inc.

LinkOut - more resources